Results | We identified 3494 hospitalizations for severe sepsis, of which 2843 (81.4%) survived to discharge. Of these, 2617 (92.1%) were matched to hospitalizations for other acute medical conditions. The cohort's mean age was 78.9 years (SD, 8.9 years), 57.3% were female, and they had some preexisting functional disability (median, 1 limitation; interquartile range [IQR], 0-4 limitations). At discharge, patients had moderate comorbidity burden (median Charlson Index, 6; IQR, 3-8). Median hospitalization length was 7 days (IQR, 4-11 days). Age, sex, co- morbidity burden, functional status, and hospitalization length did not differ between severe sepsis and matched acute medical conditions (P > .05 for each). There were 1115 severe sepsis survivors (42.6%) rehospitalized within 90 days. The 10 most common readmission diagnoses following severe sepsis included several ACSCs (eg, heart failure, pneumonia, chronic obstructive pulmonary disease exacerbation, and urinary tract infection; Table) . Collectively, ACSCs accounted for 22.2% (95% CI, 20.3%-24.5%) of 90day readmissions. Using the expanded definition, ACSCs accounted for 41.6% (95% CI, 39.1%-44.1%) of 90-day readmissions after severe sepsis.
Patterns of readmission differed between survivors of severe sepsis and matched acute medical conditions (Table and Figure) . Rates of readmission for sepsis and renal failure were higher and accounted for a greater proportion of the total readmissions after severe sepsis. Readmissions for a primary diagnosis of infection (sepsis, pneumonia, urinary tract, and skin or soft tissue infection) occurred in 11.9% (95% CI, 10.6%-13.1%) of severe sepsis survivors compared with 8.0% (95% CI, 7.0%-9.1%) of matched acute medical conditions (P < .001). Readmissions for ACSCs were more common after severe sepsis (21.6%; 95% CI, 20.0%-23.2%) vs matched acute conditions (19.1%; 95% CI, 17.7%-20.7%) (P = .02) and accounted for a greater proportion of all 90-day readmissions (41.6% [95% CI, 39.2%-44.1%] vs 37.1% [95% CI, 34.8%-39.5%], respectively; P = .009).
Discussion | Readmissions within 90 days after hospitalization for severe sepsis were common, and 42% occurred for diagnoses that could potentially be prevented or treated early to avoid hospitalization compared with 37% after matched acute medical conditions.
A limitation of the present study is that we inferred the potential preventability of rehospitalizations by measuring readmissions for ACSCs. Whether these diagnoses represent preventable admissions, especially after sepsis, is not clear. Nonetheless, the high prevalence and concentration of specific diagnoses during the early postdischarge period suggest that further study is warranted of the feasibility and potential benefit of postdischarge interventions tailored to patients' personalized risk for a limited number of common conditions. 
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COMMENT & RESPONSE
Left Atrial Appendage Closure for Atrial Fibrillation
To the Editor The study by Dr Reddy and colleagues 1 reported the 3.8-year follow-up of the PROTECT AF trial that randomized patients with atrial fibrillation (AF) to receive percutaneous left atrial appendage (LAA) closure with the WATCHMAN device or warfarin. We had a number of questions and concerns about the study.
First, patients randomized to receive warfarin were older and more often had cardiovascular comorbidities and permanent AF than the patients randomized to receive the LAA closure. In Table 1 in the article, P values were missing, so it is unclear if these differences were statistically significant and may in part explain the higher mortality in the warfarin group.
Second, why do the patient-years for the different end points in Table 2 differ? Third, after LAA closure, warfarin was discontinued for 345 of 370 patients at the 12-month transesophageal echocardiographic evaluation. What was the reason for continuation of warfarin in the remaining 25 patients, and what were their outcomes?
Fourth, according to Table 3 , 53 patients in the LAA closure group died. How many of these patients underwent autopsy, and what were the pathoanatomic findings of the left atrium and LAA? Were there any thrombi or leaks between the LAA wall and the device, and was the device completely endothelialized in all cases?
Fifth, the LAA is known to play a hemodynamic role in pressure and volume overload of the left ventricle and is a site for release of atrial natriuretic peptides. 2 Thus, it would be of interest to know whether patients in the LAA closure group developed new or worsening heart failure more frequently than patients in the warfarin group.
Sixth, only 3 of the 12 authors reported no potential conflict of interest with the manufacturer of the closure device. Furthermore, the senior author has contracted rights to receive royalties from the license of the device. The sponsor of the study was the manufacturer of the device and was responsible for data collection, analysis, interpretation, and drafting of the manuscript. Thus, a bias in favor of the device cannot be excluded. 3 Reanalysis of the data by independent scientists is needed.
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